Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01401959
Title Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC

breast cancer



Eribulin + Trastuzumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.